STAAR

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on: 
火曜日, 5月 7, 2024
General Health, Surgery, Medical Devices, Health, Optical, Sale, Near-sightedness, Table, IOL, Presbyopia, Investment, EVO, Research, Depreciation, STAAR, ICL, Patient, Access, Marketing, Adjustment, Fruit, Cataract, Advertising, Astigmatism, GAAP, Growth

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points: 
  • STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
  • Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
  • Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
  • Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
火曜日, 5月 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
水曜日, 5月 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on: 
月曜日, 4月 29, 2024
Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
  • STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

Retrieved on: 
火曜日, 4月 2, 2024
Biotechnology, Practice Management, Optical, Surgery, General Health, Health, Hospitals, Other Health, Presbyopia, ASCRS, Patient, Social media, Near-sightedness, Lens, Cataract, Astigmatism, EVO, STAAR, Surgeon, Publication, Society, Booth, FACS, Multimedia, Behavior, FDA, Reflexive relation, Communications satellite

Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.

Key Points: 
  • Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.
  • STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting .
  • View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
    “EVO ICL is the next logical step in refractive innovation.
  • The website offers surgeons access to a wealth of resources, including publications, key clinical outcomes data, and more.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 3月 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Retrieved on: 
火曜日, 3月 12, 2024
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Other Health, Eli Lilly, ICL, Boston Scientific, Growth, AstraZeneca, Presbyopia, Eli Lilly and Company, University, Near-sightedness, Art, Columbia University, Indiana State University, EVO, STAAR, Senior, MBA, Bayer, Campbell University, Nursing credentials and certifications, Marketing, CFA, Waters Corporation, Guidant, Retirement, Arthur Butcher, Economics, Astigmatism, Management

“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.

Key Points: 
  • “Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • "Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction.
  • He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
  • We wish her the best in her future endeavors.”
    With the appointment of Messrs. Butcher and Jiang to the Board, the STAAR Surgical Board is now comprised of eight directors, seven of whom are independent non-employee directors.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
月曜日, 2月 26, 2024
Optical, Health, Surgery, Medical Devices, Y/Y, Astigmatism, EVO, ICL, Research, Investment, Patient satisfaction, Marketing, Presbyopia, Growth, Table, Sale, Access, STAAR, ASCRS, Adjustment, Earnings, Advertising, GAAP, Near-sightedness, Depreciation, Pharmaceutical industry

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

STAAR Surgical to Report Fourth Quarter Results on February 26, 2024

Retrieved on: 
月曜日, 2月 19, 2024
Optical, Health, Surgery, Medical Devices, Presbyopia, Astigmatism, EVO, STAAR, Near-sightedness, Webcast

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.
  • STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 877-270-2148 for domestic participants and 412-902-6510 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .